GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches
AuthorLang, FM; Lee, KM-C; Teijaro, JR; Becher, B; Hamilton, JA
Source TitleNature Reviews Immunology
PublisherNATURE PUBLISHING GROUP
AffiliationMedicine and Radiology
Document TypeJournal Article
CitationsLang, F. M., Lee, K. M. -C., Teijaro, J. R., Becher, B. & Hamilton, J. A. (2020). GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. NATURE REVIEWS IMMUNOLOGY, 20 (8), pp.507-514. https://doi.org/10.1038/s41577-020-0357-7.
Access StatusAccess this item via the Open Access location
Open Access URLhttps://europepmc.org/articles/PMC7309428?pdf=render
Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed. Granulocyte-macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor and pro-inflammatory cytokine, plays a critical role in alveolar macrophage homeostasis, lung inflammation and immunological disease. Both administration and inhibition of GM-CSF are currently being therapeutically tested in COVID-19 clinical trials. This Perspective discusses the pleiotropic biology of GM-CSF and the scientific merits behind these contrasting approaches.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References